Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in heart failure with reduced ejection fraction
IRCT20210809052117N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Empagliflozin with Placebo (2 arms). Primary endpoints: Change in echocardiographic indicators, Change in quality of life and 2 more. Started Jun 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on IRCT20210809052117N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210809052117N1.